Tag: bipolar disorder
An Open-Label Prophylaxis Study of Lithium Plus Extended-Release Carbamazepine (ERC-CBZ) Combination for Rapid Cycling Bipolar Disorder
by Sriram Ramaswamy, MD; David Driscoll, PhD; and Lynette M. Smith, PhD Dr. Ramaswamy is with the Department of Psychiatry, Creighton University School of Medicine, Omaha, Nebraska, and the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Driscoll is with the VA Nebraska-Western Iowa Health Care System, Omaha, Nebraska. Dr. Smith is with the […]
MicroRNAs as Biomarkers for Psychiatric Conditions: A Review of Current Research
by Anoop Narahari, MD; Mariyah Hussain, MD; and Venkatesh Sreeram, MD Drs. Narahari, Hussain, and Sreeram are from the University of Alabama, Department of Psychiatry and Behavioral sciences, Birmingham, Alabama. Innov Clin Neurosci. 2017;14(1–2):53–55
Pharmaceutical Innovation in the Treatment of Schizophrenia and Mental Disorders Compared with Other Diseases
by Joanna P. MacEwan, PhD; Seth Seabury, PhD; Myrlene Sanon Aigbogun, MPH; Siddhesh Kamat, MS, MBA; Emma van Eijndhoven, MS, MA; Clement Francois, PhD; Crystal Henderson, PharmD, BCPP; and Leslie Citrome, MD, MPH Dr. MacEwan and Ms. van Eijndhoven are with Precision Health Economics in Los Angeles, California, USA; Dr. Seabury is with the University […]
Letter to the Editor: Gabapentin Abuse in a Patient with Comorbid Mood and Substance Use Disorders
Innov Clin Neurosci. 2016;13(7–8):13–14
The Neuroscience Report—Vol. 33 (January 11, 2016): Bipolar Disorder
The latest in neuroscience—sorted and summarized for you Welcome to The Neuroscience Report where each week we will highlight a specific topic in neuroscience and provide you with links to 5 journal articles, 5 news articles, and 5 wildcard picks. Brought to you by Innovations in Clinical Neuroscience—your source for peer-reviewed, evidence-based information. This week’s topic: Bipolar […]
Letter to the Editor: Comparing Injection Site Pain with Paliperidone Palmitate Versus First-generation Depot Antipsychotics in Subjects with Schizophrenia
Dear Editor: Atypical long-acting injectable (LAI) antipsychotics may improve treatment options for patients with serious mental illnesses, such as schizophrenia and bipolar disorder.[1] A systematic review of 1,700 outpatients from 10 different studies reported a 30-percent decrease in the relative risk for relapse with LAIs versus oral antipsychotic medications.[2] However, first-generation depot medications, such as […]
Lurasidone: A New Treatment Option for Bipolar Depression— A Review
by Radhika Bawa, MD, and Jonathan R. Scarff, MD Dr. Bawa is with Lehman College, the City University of New York, Bronx, New York; and Dr. Scarff is with Veterans Affairs Outpatient Clinic, Spartanburg, South Carolina. Innov Clin Neurosci. 2015;12(1–2):21–23
Systematic Study of Structured Diagnostic Procedures in Outpatient Psychiatric Rehabilitation: A Three-year, Three-cohort Study of the Stability of Psychiatric Diagnoses
by Raymond Kotwicki, MD, and Philip D. Harvey, PhD Dr. Kotwicki is with Skyland Trail and Emory University in Atlanta, Georgia; and Dr. Harvey is with the University of Miami Miller School of Medicine, Miami, Florida. Innov Clin Neurosci. 2013;10(5–6):14–19
